Imax Corp SEC Filings

IMAX — Form 144 notice of proposed sale: A holder filed to sell up to 50,143 shares of Class A Common on or about 11/07/2025 through Merrill Lynch on the NYSE, reflecting an aggregate market value of 1,738,215.

The shares to be sold were acquired on 11/07/2025 via an exercise of options under a registered plan, paid in cash. Over the prior three months, the person reported selling 20,000 shares on 09/15/2025 for gross proceeds of 656,029. Shares outstanding were 53,798,934.

IMAX Corporation completed a private Rule 144A sale of $250 million aggregate principal amount of 0.750% Convertible Senior Notes due 2030, including the full exercise of a $30 million option. The notes pay interest semi‑annually beginning May 15, 2026 and mature on November 15, 2030, unless earlier converted, redeemed, or repurchased.

Net proceeds are expected to be $241.1 million. IMAX plans to use the cash, along with cash on hand and borrowings under its credit facility, to fund capped call transactions and repurchase its 0.500% Convertible Senior Notes due 2026. The company agreed to repurchase $229.7 million principal of the 2026 notes for a total cash price of $276.0 million, including accrued interest.

The initial conversion rate is 23.5743 shares per $1,000 (conversion price ≈ $42.42) with customary adjustments; upon conversion, IMAX will settle in cash or cash plus shares. The capped call’s initial cap price is $57.1025 (a 75% premium to the November 3, 2025 close) and cost approximately $21.9 million. The notes are redeemable at IMAX’s option on or after November 20, 2028 if the share price exceeds 130% of the conversion price for the specified trading periods. An initial maximum of 7,661,650 shares may be issuable upon conversion based on the initial maximum conversion rate.

IMAX Corporation filed its Q3 2025 report, showing higher revenue and profit. Revenue for the quarter was $106.654 million, up from $91.452 million a year ago, as stronger image enhancement and maintenance services ($61.029 million) and technology rentals ($23.336 million) offset lower technology sales ($19.360 million). Gross margin rose to $67.271 million from $51.019 million, and income from operations increased to $29.045 million from $19.411 million.

Net income attributable to common shareholders was $20.657 million, or diluted EPS of $0.37, versus $13.896 million and $0.26 last year. Year‑to‑date operating cash flow reached $97.694 million, supporting cash and cash equivalents of $143.106 million as of September 30, 2025. Total assets were $889.573 million and total shareholders’ equity was $435.986 million. Debt consisted of $230.743 million in convertible notes and other borrowings and $26.477 million outstanding on the revolving credit facility. Deferred revenue increased to $64.505 million. Common shares outstanding were 53,798,934 as of September 30, 2025.

IMAX Corporation furnished a press release announcing its financial and operating results for the quarter ended September 30, 2025, under Item 2.02 of a Form 8-K.

The release is attached as Exhibit 99.1. The information is furnished, not filed, which means it is not subject to Section 18 of the Exchange Act and will be incorporated by reference only if specifically stated.

Robert D. Lister, Chief Legal Officer and Senior Executive Vice President of IMAX Corporation, reported a sale of common stock. On 09/15/2025 Mr. Lister sold 20,000 shares at a reported price of $32.80 per share under a 10b5-1 trading plan dated June 11, 2025. After the sale his reported beneficial ownership of common shares is 161,421. The filing also discloses his remaining equity holdings across compensation vehicles: 50,143 outstanding options and 70,609 restricted share units following the transaction. The Form 4 was filed individually and signed by an attorney-in-fact on Mr. Lister's behalf.

IMAX Corp filed a Form 144 to notify a proposed sale of 20,000 Class A Common Shares through Merrill Lynch on the NYSE with an approximate sale date of 09/15/2025. The filing reports an aggregate market value of $656,029 against 53,782,520 shares outstanding, indicating the sale represents a small fraction of the company's outstanding stock.

The 20,000 shares were acquired through vesting of restricted stock units (RSUs) issued as compensation on dates between 02/21/2018 and 03/07/2021 (2,456; 1,869; 15,203; 472 respectively). No securities sales by the filer in the past three months are reported, and the filer certifies no undisclosed material adverse information.

Kenneth Ian Weissman, IMAX Corp executive (Deputy General Counsel, Corporate Secretary & Chief Compliance Officer), reported option exercise and subsequent share sales on 08/14/2025. He exercised 7,072 stock options with an exercise price of $22.49 (options issued in 2019, expiring 03/07/2026) converting them into 7,072 common shares. The filing shows two dispositions the same day: sale of 7,072 shares at $25.6707 and sale of 8,000 shares at $25.6272.

Ownership changed from an opening balance of 34,133 common shares to a post-transaction balance of 26,133 common shares. The filing notes Mr. Weissman retains 17,021 restricted share units outstanding and that the exercised options were vested in installments between 2020 and 2023.

Form 144 notice for IMAX (IMAX) reports a proposed sale of 15,072 common shares through Morgan Stanley Smith Barney, with an aggregate market value of $386,560.79 based on 53,782,520 shares outstanding. The approximate sale date is 08/14/2025 on the NYSE. The lots to be sold were largely acquired through restricted stock vesting on 03/07/2023 (multiple grants totaling 8,867 shares) and earlier vesting on 03/07/2021 (233 shares), plus an option exercise scheduled 08/14/2025 for 7,072 shares paid in cash. The filer states no securities of the issuer were sold in the past three months and attests they are not aware of undisclosed material adverse information.